COCH Stock Forecast 2025-2026
Distance to COCH Price Targets
COCH Price Momentum
10 Quality Stocks Worth Considering Now
Researching Envoy Medical (COCH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on COCH and similar high-potential opportunities.
Latest COCH Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, COCH has a bullish consensus with a median price target of $7.00 (ranging from $5.00 to $9.00). Currently trading at $1.34, the median forecast implies a 422.4% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Woo at Ascendiant Capital, projecting a 571.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COCH Analyst Ratings
COCH Price Target Range
Latest COCH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COCH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 6, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $9.00 |
| Oct 14, 2024 | Brookline Capital | Tyler Bussian | Buy | Initiates | $9.00 |
| Sep 3, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $8.75 |
| Jun 24, 2024 | Ascendiant Capital | Edward Woo | Buy | Initiates | $8.50 |
| Apr 3, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $6.00 |
| Dec 21, 2023 | Northland Capital Markets | Carl Byrnes | Outperform | Initiates | $0.00 |
| Nov 28, 2023 | Lake Street | Frank Takkinen | Buy | Initiates | $3.00 |
Envoy Medical, Inc. (COCH) Competitors
The following stocks are similar to Envoy Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Envoy Medical, Inc. (COCH) Financial Data
Envoy Medical, Inc. has a market capitalization of $28.58M with a P/E ratio of 0.0x. The company generates $225,000 in trailing twelve-month revenue with a -229.8% profit margin.
Revenue growth is -55.8% quarter-over-quarter, while maintaining an operating margin of -10,771.4% and return on equity of +148.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Envoy Medical, Inc. (COCH) Business Model
About Envoy Medical, Inc.
Develops innovative medical devices for hearing healthcare.
Envoy Medical generates revenue by designing and developing advanced medical devices specifically for individuals with hearing loss. Their flagship products utilize cutting-edge technology to enhance auditory performance, aiming to improve patient outcomes and quality of life.
The company operates within the broader medical device industry, impacting sub-sectors such as audiology and otolaryngology. Envoy Medical emphasizes research and development, contributing to innovative hearing health technologies that integrate into medical practices globally. They are committed to addressing the needs of the growing demographic requiring advanced hearing aid solutions.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
42
CEO
Mr. Brent T. Lucas Esq.
Country
United States
IPO Year
2023
Website
www.envoymedical.comEnvoy Medical, Inc. (COCH) Latest News & Analysis
Envoy Medical (NASDAQ: COCH) reported positive progress in enrolling subjects for its pivotal study on the Acclaim® Cochlear Implant and shared strong corporate results for 2024.
Envoy Medical's progress in its pivotal clinical study for the Acclaim® Cochlear Implant signals potential advancements in product development, impacting future revenue and stock performance.
Envoy Medical (NASDAQ: COCH) announced the reintroduction of the Hearing Device Coverage Clarification Act, aiming to classify certain hearing implants as prosthetics for potential Medicare coverage.
Clarification on hearing implant coverage could expand Medicare benefits, potentially increasing demand for Envoy Medical's products and enhancing revenue prospects, impacting stock performance.
Envoy Medical, Inc. secured $10 million in financing from its largest shareholder, Glen Taylor, supporting its growth and key initiatives for the year.
Glen Taylor's $10 million investment signals confidence in Envoy Medical's growth potential, which may boost investor sentiment and stock value during key developments.
Envoy Medical, Inc. (NASDAQ: COCH) will participate in the 37th Annual ROTH Conference from March 16-18, 2025, in Dana Point, California, with CEO Brent Lucas attending.
Envoy Medical's participation in a major conference highlights its growth potential and innovation in hearing technology, which could attract investor interest and affect stock performance.
Envoy Medical (NASDAQ: COCH) has enrolled the first two participants in its pivotal clinical study for the Acclaim® cochlear implant, aimed at supporting its premarket approval application.
Successful enrollment in Envoy Medical's clinical study for the Acclaim® cochlear implant signals progress toward FDA approval, potentially boosting stock value and market position in hearing health.
Envoy Medical (NASDAQ: COCH) announced the issuance of additional patents by the US Patent & Trademark Office, enhancing its intellectual property portfolio in hearing health solutions.
Envoy Medical's new patents enhance its competitive edge, potentially leading to increased market share and revenue, making it a more attractive investment opportunity.
Frequently Asked Questions About COCH Stock
What is Envoy Medical, Inc.'s (COCH) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Envoy Medical, Inc. (COCH) has a median price target of $7.00. The highest price target is $9.00 and the lowest is $5.00.
Is COCH stock a good investment in 2025?
According to current analyst ratings, COCH has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.34. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COCH stock?
Wall Street analysts predict COCH stock could reach $7.00 in the next 12 months. This represents a 422.4% increase from the current price of $1.34. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Envoy Medical, Inc.'s business model?
Envoy Medical generates revenue by designing and developing advanced medical devices specifically for individuals with hearing loss. Their flagship products utilize cutting-edge technology to enhance auditory performance, aiming to improve patient outcomes and quality of life.
What is the highest forecasted price for COCH Envoy Medical, Inc.?
The highest price target for COCH is $9.00 from Edward Woo at Ascendiant Capital, which represents a 571.6% increase from the current price of $1.34.
What is the lowest forecasted price for COCH Envoy Medical, Inc.?
The lowest price target for COCH is $5.00 from at , which represents a 273.1% increase from the current price of $1.34.
What is the overall COCH consensus from analysts for Envoy Medical, Inc.?
The overall analyst consensus for COCH is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are COCH stock price projections?
Stock price projections, including those for Envoy Medical, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.